The U.S. has given the final go-ahead to the nation’s first COVID-19 vaccine, launching emergency vaccinations in a bid to end the pandemic. Shots will begin in a few days after Friday’s decision by the Food and Drug Administration. The FDA called the vaccine from Pfizer and its German partner BioNTech safe and strongly protective. But initial doses are scarce…
WASHINGTON (AP) – Pfizer’s COVID-19 vaccine faces one final hurdle before an expected decision to greenlight the shot for use in millions of Americans. Food and Drug Administration advisers meet Thursday to scrutinize the company’s data for any red flags or oversights. The public review comes as U.K. regulators investigate two apparent cases of allergic reaction to the vaccine. Safety…
Courtesy: Ap News WASHINGTON (AP) – President Donald Trump aims to take credit for the speedy development of forthcoming coronavirus vaccines, even as his administration is coming under scrutiny for allegedly failing to lock in a chance to buy millions of additional doses of one of the leading coronavirus vaccine contenders this summer. That decision could delay the delivery of…
Pfizer is set to ask U.S. regulators to allow emergency use of its COVID-19 vaccine, starting a process that could bring first shots as early as next month. Friday’s step comes days after Pfizer and its German partner BioNTech announced its vaccine appears 95% protective in a large but not yet finished study. Over the next few weeks, the Food…
Pfizer has announced more results in its ongoing coronavirus vaccine study that suggest the shots are 95% effective. The company also said that the vaccine appears to protect older people most at risk of dying from COVID-19. The surprise announcement, just a week after it first revealed promising preliminary results, comes as the company is preparing within days to formally…
Pfizer says an early peek at its vaccine data suggests the shots may be 90% effective at preventing COVID-19. Monday’s announcement doesn’t mean a vaccine is imminent. The interim analysis, from independent data monitors, looked at 94 infections recorded so far in a study that has enrolled nearly 44,000 people. Pfizer did not provide any more details about those cases,…
